EBMT 2024 | Young matched unrelated donors versus older-aged matched sibling donors in alloSCT with PTCy
Karthik Nath, MBBS, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, presents findings from a retrospective analysis of the CIBMTR registry comparing outcomes of young matched unrelated donors (MUD) versus older-aged matched sibling donors (MSD) in allogeneic stem cell transplantation (alloSCT) for older patients who have received post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GvHD) prophylaxis. The analysis included over 3700 patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or myelodysplastic syndromes (MDS). Results indicate improved overall survival (OS) in the MUD cohort, suggesting a preference for MUD aged 35 or younger over older-aged MSD. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
